ArticlePloS one2015
Variation in Bordetella pertussis Susceptibility to Erythromycin and Virulence-Related Genotype Changes in China (1970-2014).
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antimicrobial resistance inEpidemiology and infection · 2026Pooled it
- Comment on "sharp rise in high-virulenceEmerging microbes & infections · 2026Article
- IS481-based pertussis positivity transition from preschool to school-aged children and theEmerging microbes & infections · 2026Article
- Expert consensus on competency enhancement of pertussis prevention, diagnosis, and management for healthcare professionals through medical-preventive integration.Infectious diseases & immunity · 2026Article
- Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis.The Journal of antimicrobial chemotherapy · 2026Article
- Epidemiological and clinical characteristics of macrolide-resistant Bordetella pertussis in southern China: an 8-year retrospective study.BMC infectious diseases · 2026Article
- A retrospective, single-center analysis of clinical features and mortality risk factors in pediatric pertussis patients with severe pneumonia and encephalopathy complications in Southwest China.Italian journal of pediatrics · 2026Article
- Sharp rise in high-virulence Bordetella pertussis with macrolides resistance in Northern China.Emerging microbes & infections · 2025Article
- A pathogen peptidoglycan scaffold coated with artificial biomembrane promotes broad resistance to bacterial infections by dynamically reprogramming macrophage metabolism.Materials today. Bio · 2025Article
- Analysis of pertussis surveillance data (2022-2023) in a district of Beijing.BMC infectious diseases · 2025Article
- Molecular epidemiology and increasing macrolide resistance of Bordetella pertussis isolates in Guangzhou, China.BMC infectious diseases · 2025Article
- Macrolide-ResistantMicroorganisms · 2025Article
- Waning immunity, prevailing non-vaccine typeThe Lancet regional health. Western Pacific · 2025Article
- Article
- Lonidamine, a Novel Modulator for the BvgAS System of Bordetella Species.Microbiology and immunology · 2025Article
- Molecular epidemiological characteristics of pertussis in a pediatric hospital in Jinan City, China, 2022 to 2024.Frontiers in public health · 2025Article
- Molecular characterization and antimicrobial susceptibility for 62 isolates ofFrontiers in microbiology · 2024Article
- Screening of Novel Drug Targets and Drug Design forCurrent research in microbial sciences · 2024Article
- The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Review
- Molecular Evolution and Increasing Macrolide Resistance of Bordetella pertussis, Shanghai, China, 2016-2022.Emerging infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate changes in virulence-related genotypes and in the antimicrobial susceptibility of Bordetella pertussis isolates collected from the 1970s to 2014 in the northern part of China.
methodsA total of 124 B. pertussis isolates from three periods, the 1970s, 2000-2008, and May 2013-Sept 2014, were typed by multilocus sequence typing (MLST) and tested for antimicrobial susceptibility and virulence-related genes. A fragment of the 23S rRNA gene from each of the 99 isolates from 2013-2014 was amplified and sequenced.
resultsAll isolates from 2000-2008 and 2013-2014 were identified as ST2, whereas isolates from the 1970s were ST1. PtxA2/ptxC1/ptxP1/prn1/fim2-1/fim3-1/tcfA2, which was the same as the vaccine strain, was the only type in the 1970s. During the 2000s and 2013-2014, the virulence type ptxA1/ptxC1/ptxP1/prn1/fim2-1/fim3-1/tcfA2 was dominant, with frequencies of 68.4% and 91.9%, respectively. Nine ptxP3 strains, which were more virulent, were detected after 2000. All 124 isolates were susceptible to levofloxacin, sulphamethoxazole/trimethoprim and tetracycline. The isolates from the 1970s and 2000-2008 were susceptible to all tested macrolides, whereas 91.9% of the 2013-2014 isolates were highly resistant (minimal inhibitory concentration, MIC >256 μg/ml). No ptxP3 strain was resistant to macrolides. All erythromycin-resistant strains except for one had the A2047G mutation in the 23S rRNA gene.
conclusionsMacrolide resistance of the B. pertussis population has been a serious problem in the northern part of China. Because most of the epidemic clone of the pathogen expresses the same antigen profiles as the vaccine strain, except ptxA, improvements in immunization strategies may prevent the spread of infection and drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.